| DC vaccine |
II |
Hepatocellular Cancer Colorectal Cancer |
Nivolumab |
NCT04912765 |
| DNA vaccine |
I/II |
Hepatocellular Cancer |
NO-9012 Pembrolizumab |
NCT04251117 |
|
II |
Small Cell Lung Cancer |
Durvalumab |
NCT04397003 |
| mRNA vaccine |
/ |
Gastric Cancer Esophageal Cancer Liver Cancer |
PD-1/L1 |
NCT05192460 |
| SLP vaccine |
I |
Pancreatic Cancer Metastatic Colorectal Cancer Metastatic |
Retifanlimab |
NCT04799431 |
|
I/II |
Melanoma Ocular Melanoma Uveal Melanoma |
6MHP PolyICLC CDX-1140 |
NCT04364230 |
|
I |
Squamous Cell Lung Cancer Squamous Non-small Cell Lung Cancer Squamous Cell Carcinoma of Head and Neck |
Pembrolizumab |
NCT04266730 |
| TIL |
I |
Epithelial Tumors |
NMA-LD Regimen Interleukin-2 |
NCT05141474 |
| TCR-T |
II |
Endocrine Tumors Non-Small Cell Lung Cancer Ovarian Cancer Breast Cancer Gastrointestinal/Genitourinary Cancers Neuroendocrine Tumors Multiple Myeloma |
Cyclophosphamide Fludarabine Aldesleukin Pembrolizumab |
NCT03412877 |
|
II |
Non-Small Cell Lung Cancer Breast Cancer Gastrointestinal/Genitourinary Cancers Ovarian Cancer |
Fludarabine Cyclophosphamide Aldesleukin |
NCT04102436 |
| CAR-T |
I |
Glioblastoma |
Pembrolizumab |
NCT03726515 |
